# Bioequivalence of Azathioprine Suspension 10 mg/mL (Jayempi) Versus Azathioprine Tablet 50mg (Imurek®)

> **NCT03930264** · PHASE1 · COMPLETED · sponsor: **Nova Laboratories Limited** · enrollment: 30 (actual)

## Conditions studied

- Therapeutic Equivalency

## Interventions

- **DRUG:** Azathioprine 50Mg Tab
- **DRUG:** Azathioprine 10mg/mL oral suspension

## Key facts

- **NCT ID:** NCT03930264
- **Lead sponsor:** Nova Laboratories Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-11
- **Primary completion:** 2019-05-24
- **Final completion:** 2019-05-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-06-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03930264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03930264, "Bioequivalence of Azathioprine Suspension 10 mg/mL (Jayempi) Versus Azathioprine Tablet 50mg (Imurek®)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03930264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*